Last week, life sciences patent professionals from around the world gathered at London’s Hallam Conference Centre for IAM’s second annual Pharma and Biotech IP Summit – the first ever IAM event to be held on UK home turf. Delegates – and there were twice as many in attendance than were at our first summit in Munich in 2016 – were treated to insightful presentations and discussions by seasoned in-house and private practice professionals on a range of key legal, strategic and policy-related topics.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Straight talk on key IP issues, IAM aims to provide executive managers with the business perspective that often gets lost in technical jargon and legal details.

Gene Potkay
Senior vice president of intellectual property
The Nielsen Company


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?